Invasive meningococcal disease in children in Jerusalem

Epidemiology and Infection

Volumn 136, Issue 6, 2008, Pages 782-789

  Stein Zamir, Chen ^a   Abramson, N ^a   Zentner, G ^a   Shoob, H ^a   Valinsky, L ^b   Block, C ^c  

^a Jerusalem District Health Office   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE;

ADOLESCENT; ARAB; ARTICLE; BACTERIUM ISOLATION; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; CHILD; CHILDHOOD DISEASE; EPIDEMIC MENINGITIS; FATALITY; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; ISRAEL; JEW; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; MORTALITY; NEISSERIA MENINGITIDIS; PULSED FIELD GEL ELECTROPHORESIS; RISK ASSESSMENT; SEPTICEMIA;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; DISEASE OUTBREAKS; DNA FINGERPRINTING; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; GENOTYPE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ISRAEL; MALE; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS; SEROTYPING; SOCIOECONOMIC FACTORS;

EID: 42149147276     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807009259     Document Type: Article

References (41)

1. Whitney CG, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003; 348: 1737-1746.
2. Schuchat A, et al. for the Active Surveillance Team. Bacterial meningitis in the United States in 1995. New England Journal of Medicine 1997; 337: 970-976.
3. Pollard AJ, Moxon ER. The meningococcus tamed? Archives of Disease in Childhood 2002; 87: 13-17.
4. Rosenstein NE, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. Journal of Infectious Diseases 1999; 180: 1894-1901.
5. American Public Health Association. In: Heymann DL, ed. Control of Communicable Diseases Manual, 18th edn. Washington, 2004, p. 359.
6. Nadel S, Kroll JS. Diagnosis and management of meningococcal disease: The need for centralized care. FEMS Microbiology Reviews 2007; 31: 71-83.
7. Rosenstein NE, et al. Meningococcal disease. New England Journal of Medicine 2001; 344: 1378-1388.
8. Dankert J. Neisseria. In: Cohen J, Powderly WG, eds. Infectious Diseases, 2nd edn. Edinburgh: Mosby, 2004, pp. 2173-2186.
9. Lapeyssonnie L. Cerebrospinal meningitis in Africa [in French]. Bulletin of the WHO 1963; 28 (Suppl.): 3-114.
10. Wang JF, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infection and Immunity 1992; 60: 5267-5282.
11. Tsolia MN, et al. The evolving epidemiology of invasive meningococcal disease: A two-year prospective, population-based study in children in the area of Athens. FEMS Immunology and Medical Microbiology 2003; 36: 87-94.
12. Block C, et al. Forty years of meningococcal disease in Israel 1951-1990. Clinical Infectious Disease 1993; 17: 126-132.
13. Williams CJ, et al. Geographic correlation between deprivation and risk of meningococcal disease: An ecological study. BMC Public Health 2004; 4: 30.
14. Heyderman RS, et al. The incidence and mortality for meningococcal disease associated with area deprivation: An ecological study of hospital episode statistics. Archives of Disease in Childhood 2004; 89: 1064-1068.
15. Fone DL, et al. Meningococcal disease and social deprivation: A small area geographical study in Gwent, UK. Epidemiology and Infection 2003; 30: 53-58.
16. Pereiró I, et al. Risk factors for invasive disease among children in Spain. Journal of Infection 2004; 48: 320-329.
17. Deutch S, et al. Crowding as a risk factor of meningococcal disease in Danish preschool children: A nationwide population-based case-control study. Scandinavian Journal of Infectious Diseases 2004; 36: 20-23.
18. Centres for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weeekly Report 2005; 54 (No. RR-7): 1-21.
19. Centres for Diseases Control and Prevention. Standardized molecular subtyping of foodborne bacterial pathogens by pulsed-field gel electrophoresis. CDC training manual. Centres for Disease Control and Prevention, Atlanta, GA, 2000.
20. Ministry of Health, Israel. Weekly Epidemiological Reports 1999-2005, Department of Epidemiology, Public Health Services, Ministry of Health, Israel (http://www.health.gov.il).
21. Central Bureau of Statistics. Statistical Abstract of Israel 2005-No.56. Chapter 2. Population. Table 2.7 Localities and population by district, sub-district, area, population group and religion. State of Israel. Central Bureau of Statistics. Jerusalem 2005.
22. Statistical Yearbook of Jerusalem 2005. Choshen M, ed. Chapter III, Population Table III/12 - Population of Jerusalem, by Population Group and Age, 1997-2003. Jerusalem, 2005.
23. Hoebe CJ, et al. Space-time cluster analysis of invasive meningococcal disease. Emerging Infectious Diseases 2004; 10 1621-1626.
24. Abramson JH. WINPEPI (PEPI-for-Windows): Computer programs for epidemiologists. Epidemiologic Perspectives & Innovations 2004; 1: 6.
25. American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, ed. 2003 Red Book: Report of the Committee on Infectious Diseases, 26th edn. Elk Grove Village, IL. American Academy of Pediatrics, 2003, pp. 430-432.
26. Almog R, et al. First recorded outbreaks of meningococcal disease in the Israel Defence Force: Three clusters due to serogroup C and the emergence of resistance to rifampicin. Infection 1994; 22: 69-71.
27. Shehab S, et al. Failure of mass antibiotic prophylaxis to control a prolonged outbreak of meningococcal disease in an Israeli village. European Journal of Clinical Microbiology and Infectious Diseases 1998; 17: 749-753.
28. Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: Database study. British Medical Journal 2003; 327: 596-597.
29. Sharip A, et al. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatric Infectious Disease Journal 2006; 25: 191-194.
30. Smith I, et al. Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002. Epidemiology and Infection 2006; 134: 103-110.
31. Jackson LA, Wenger JD. Laboratory-Based Surveillance for Meningococcal Disease in Selected Areas, United States, 1989-1991. Morbidity and Mortality Weeekly Report. Surveillance Summaries 1993; 42 (SS-2); 21-30.
32. Purcell B, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: Systematic review. British Medical Journal 2004; 328: 1339.
33. Ministry of Health Israel. Public Health Services, Department of Epidemiology. In: Immunization Guidelines 1999, Chap. 16. Meningococcal Disease p. 2-7 (Chemoprophylaxis). Jerusalem, Israel, 1999.
34. Davison KL, et al. Clusters of meningococcal disease in school and preschool settings in England and Wales: What is the risk? Archives of Diseases in Childhood 2004; 89: 256-260.
35. Yazdankhah SP, Lindstedt BA, Caugant DA. Use of variable-number tandem repeats to examine genetic diversity of Neisseria meningitidis. Journal of Clinical Microbiology 2005; 43: 1699-1705.
36. Trotter C, et al. Ascertainment of meningococcal disease in Europe. Eurosurveillance 2005; 10: 247-250.
37. Holst J, et al. The concept of 'tailor-made', protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23: 2202-2205.
38. O'Hallahan J, et al. From secondary prevention to primary prevention: A unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005; 23: 2197-2201.
39. Hall RG. The control of meningococcal disease. Medical Journal of Australia 2002; 176: 573-574.
40. Perrett KP, Pollard AJ. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opinion on Biological Therapy 2005; 5: 1611-1625.
41. Girard MP, et al. A review of vaccine research and development: Meningococcal disease. Vaccine 2006; 24: 4692-4700.